A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 07 Mar 2018
At a glance
- Drugs Tivozanib (Primary)
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
- 28 Feb 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Jan 2019.
- 10 Jun 2017 Biomarkers information updated
- 27 Mar 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Jan 2018.